Collectively, these effects lead to improved glycemic control in individuals diagnosed with type 2 diabetes
Sources U.S
In our study, we evaluated efficacy for a wider range of patients
Drug Interactions Drugs that may increase the risk of hypoglycemia: antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), and sulfonamide antibiotics
This is exactly what we set out to prove when we launched Noom GLP-1 Rx : medication can accelerate progress, but behavior change sustains it
Importantly, empagliflozin also slowed kidney disease progression in participants with minimal albuminuria [54]